Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study

Overview

Journal Nutrients

Date 2021 Feb 11

PMID 33567701

Citations 36

Authors

Akio Kanazawa

Masanori Aida

Yasuto Yoshida

Hideyoshi Kaga

Takehiro Katahira

Luka Suzuki

Shoko Tamaki

Junko Sato

Hiromasa Goto

Kosuke Azuma

Tomoaki Shimizu

Takuya Takahashi

Yuichiro Yamashiro

Hirotaka Watada

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic ( strain Shirota (previously strain Shirota) and strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. -0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of and total lactobacilli, the relative abundances of species such as and , and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes.

Citing Articles

Gerobiotics: Exploring the Potential and Limitations of Repurposing Probiotics in Addressing Aging Hallmarks and Chronic Diseases.

Mahamud A, Tanvir I, Kabir M, Samonty I, Chowdhury M, Rahman M Probiotics Antimicrob Proteins. 2025; .

PMID: 40029460 DOI: 10.1007/s12602-025-10501-w.

Exploring Inflammatory Changes in the Peripheral Blood of Type 2 Diabetes Mellitus in China.

Li D, Zhang Z, Li W, Zhao C, Li X, Pan Z J Inflamm Res. 2025; 18:1679-1688.

PMID: 39925936 PMC: 11806746. DOI: 10.2147/JIR.S501105.

Impact of Gut Microbiome Interventions on Glucose and Lipid Metabolism in Metabolic Diseases: A Systematic Review and Meta-Analysis.

Mederle A, Dima M, Stoicescu E, Capastraru B, Levai C, Hategan O Life (Basel). 2024; 14(11).

PMID: 39598283 PMC: 11595434. DOI: 10.3390/life14111485.

Effectiveness and safety study of formula containing probiotics, prebiotics, synbiotics on fullterm infants' growth - a systematic review and meta-analysis of randomized controlled study.

Qian J, Fang Z, Chang S, Zeng Z, Zhang J Eur J Clin Nutr. 2024; .

PMID: 39448812 DOI: 10.1038/s41430-024-01506-9.

Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches.

Acevedo-Roman A, Pagan-Zayas N, Velazquez-Rivera L, Torres-Ventura A, Godoy-Vitorino F Int J Mol Sci. 2024; 25(17).

PMID: 39273662 PMC: 11396321. DOI: 10.3390/ijms25179715.

References

Fujimoto J, Matsuki T, Sasamoto M, Tomii Y, Watanabe K . Identification and quantification of Lactobacillus casei strain Shirota in human feces with strain-specific primers derived from randomly amplified polymorphic DNA. Int J Food Microbiol. 2008; 126(1-2):210-5. DOI: 10.1016/j.ijfoodmicro.2008.05.022. View

Tolhurst G, Heffron H, Lam Y, Parker H, Habib A, Diakogiannaki E . Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2011; 61(2):364-71. PMC: 3266401. DOI: 10.2337/db11-1019. View

De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A . Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014; 156(1-2):84-96. DOI: 10.1016/j.cell.2013.12.016. View

Mohamadshahi M, Veissi M, Haidari F, Shahbazian H, Kaydani G, Mohammadi F . Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. Bioimpacts. 2014; 4(2):83-8. PMC: 4097976. DOI: 10.5681/bi.2014.007. View

Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K . Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol. 2006; 73(1):32-9. PMC: 1797142. DOI: 10.1128/AEM.01224-06. View

Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T . Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer. Dig Dis Sci. 2013; 58(6):1717-26. DOI: 10.1007/s10620-012-2526-4. View

Pedersen H, Gudmundsdottir V, Nielsen H, Hyotylainen T, Nielsen T, Jensen B . Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016; 535(7612):376-81. DOI: 10.1038/nature18646. View

Zeng Z, Luo J, Zuo F, Yu R, Zhang Y, Ma H . Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV. Lett Appl Microbiol. 2015; 62(3):250-5. DOI: 10.1111/lam.12510. View

Karlsson F, Tremaroli V, Nookaew I, Bergstrom G, Behre C, Fagerberg B . Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498(7452):99-103. DOI: 10.1038/nature12198. View

10.

Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, Kyriienko D, Komissarenko I . Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial. Diabetes Metab Syndr. 2018; 12(5):617-624. DOI: 10.1016/j.dsx.2018.04.015. View

11.

Mehta N, McGillicuddy F, Anderson P, Hinkle C, Shah R, Pruscino L . Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. 2009; 59(1):172-81. PMC: 2797919. DOI: 10.2337/db09-0367. View

12.

Fujimoto J, Tanigawa K, Kudo Y, Makino H, Watanabe K . Identification and quantification of viable Bifidobacterium breve strain Yakult in human faeces by using strain-specific primers and propidium monoazide. J Appl Microbiol. 2010; 110(1):209-17. DOI: 10.1111/j.1365-2672.2010.04873.x. View

13.

Cornejo-Pareja I, Martin-Nunez G, Roca-Rodriguez M, Cardona F, Coin-Araguez L, Sanchez-Alcoholado L . Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans. J Clin Med. 2019; 8(4). PMC: 6517938. DOI: 10.3390/jcm8040451. View

14.

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

15.

Wan Saudi W, Sjoblom M . Short-chain fatty acids augment rat duodenal mucosal barrier function. Exp Physiol. 2017; 102(7):791-803. DOI: 10.1113/EP086110. View

16.

Matsuki T, Pedron T, Regnault B, Mulet C, Hara T, Sansonetti P . Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breve. PLoS One. 2013; 8(4):e63053. PMC: 3639975. DOI: 10.1371/journal.pone.0063053. View

17.

Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T . The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013; 4:1829. PMC: 3674247. DOI: 10.1038/ncomms2852. View

18.

Sanchis-Chorda J, Gomez Del Pulgar E, Carrasco-Luna J, Benitez-Paez A, Sanz Y, Codoner-Franch P . Bifidobacterium pseudocatenulatum CECT 7765 supplementation improves inflammatory status in insulin-resistant obese children. Eur J Nutr. 2018; 58(7):2789-2800. DOI: 10.1007/s00394-018-1828-5. View

19.

Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H . Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care. 2014; 37(8):2343-50. DOI: 10.2337/dc13-2817. View

20.

Nagpal R, Tsuji H, Takahashi T, Kawashima K, Nagata S, Nomoto K . Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section. Front Microbiol. 2016; 7:1997. PMC: 5156933. DOI: 10.3389/fmicb.2016.01997. View